Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >

Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! ↗

April 21, 2023

Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid...

Via Benzinga

Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer ↗

April 10, 2023

Via Benzinga

Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories ↗

April 03, 2023

Bloomberg UBS Prepping For Massive Layoffs Amid Credit Suisse Takeover

Via Benzinga

National Institute on Aging Aims Building $300M Alzheimer's Research Database ↗

April 03, 2023

The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...

Via Benzinga

Daily Stock Analysis: Eisai ↗

March 13, 2023

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's activities consist of a pharmaceutical business and other businesses.

Via Talk Markets

Lecanemab Receives Priority Review Status in Japan

January 29, 2023

From Eisai

Via JCN Newswire

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

January 09, 2023

From Eisai

Via JCN Newswire

FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

January 09, 2023

From Eisai

Via JCN Newswire

Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug ↗

March 31, 2023

Via Benzinga

7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments ↗

March 16, 2023

Via Benzinga

Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity ↗

March 14, 2023

Via Benzinga

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment ↗

March 06, 2023

Via Benzinga

1 Green Flag and 1 Red Flag for Biogen ↗

December 23, 2022

Biogen beat the bear market this year.

Via The Motley Fool

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

December 22, 2022

From Eisai

Via JCN Newswire

Why Anavex Life Sciences Stock Bolted Higher in January ↗

February 08, 2023

The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.

Via The Motley Fool

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback? ↗

January 25, 2023

Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.

Via The Motley Fool

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug ↗

January 20, 2023

The company will need to complete its confirmatory study before asking for approval.

Via Investor's Business Daily

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval ↗

January 19, 2023

The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.

Via The Motley Fool

This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich ↗

January 17, 2023

The fountain of youth might not be a myth in the future.

Via The Motley Fool

Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval? ↗

January 10, 2023

There's more to the story with Biogen after receiving good news for Leqembi.

Via The Motley Fool

Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill ↗

January 07, 2023

Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.

Via Benzinga

FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway ↗

January 06, 2023

Via Benzinga

Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock? ↗

January 06, 2023

Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock.

Via InvestorPlace

Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite? ↗

January 06, 2023

CMS already snubbed Biogen's first Alzheimer's drug. Will the second fare better?

Via Investor's Business Daily

1 Stock Defying the Downturn to Buy, and 1 to Avoid ↗

January 06, 2023

These two stocks might go in different directions in the future.

Via The Motley Fool

Top Picks For 2023: Catalyst Pharmaceuticals ↗

January 02, 2023

Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...

Via Talk Markets

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Biogen's Alzheimer's Antibody Might Have A Third Death Associated With ↗

December 22, 2022

A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.